Compare QTRX & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTRX | DERM |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 135.3M |
| IPO Year | 2017 | 2021 |
| Metric | QTRX | DERM |
|---|---|---|
| Price | $3.37 | $5.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.00 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 877.3K | 165.2K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | N/A | ★ N/A |
| Revenue | $37,632,000.00 | ★ $61,858,000.00 |
| Revenue This Year | $25.49 | $39.72 |
| Revenue Next Year | $10.04 | $63.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 64.52 | 10.20 |
| 52 Week Low | $2.95 | $4.31 |
| 52 Week High | $8.77 | $9.56 |
| Indicator | QTRX | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 42.16 |
| Support Level | $3.30 | $4.31 |
| Resistance Level | $3.81 | $5.50 |
| Average True Range (ATR) | 0.24 | 0.28 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 54.25 | 38.00 |
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.